GlassScriptPhysician profile
Rodrick Stewart
NPI 1134507171
$4,045.56
in general payments reported to CMS, 2019-2025
33 companies · $967 in 2025
The $967 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.92 · 2021: $263 · 2022: $473 · 2023: $1,170 · 2024: $1,148 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.06 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $668.34 | 2023-2025 | Apretude, Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $546.50 | 2021-2024 | Dificid, Pifeltro, Delstrigo |
| Gilead Sciences, INC. | $461.95 | 2022-2025 | |
| Novo Nordisk INC | $287.53 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Theratechnologies INC. | $241.69 | 2021-2024 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $172.30 | 2020-2023 | Symtuza |
| Emd Serono, INC. | $167.12 | 2021-2024 | Serostim |
| Abbvie INC. | $151.17 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $140.90 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.83 | 2023-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $107.69 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.38 | 2024-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $85.22 | 2024-2025 | Breztri, Airsupra |
| Amgen INC. | $76.13 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $73.96 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $70.25 | 2024-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $60.70 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $58.69 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $49.57 | 2025 | Neffy |
| Lundbeck LLC | $43.44 | 2023-2024 | Rexulti |
| Napo Pharmaceuticals INC | $41.28 | 2024 | Mytesi |
| Idorsia Pharmaceuticals US INC | $40.88 | 2023 | Quviviq |
| Abbott Laboratories | $40.34 | 2024-2025 | Freestyle Libre 3 |
| Halozyme INC | $36.94 | 2023 | |
| Antares Pharma, INC. | $35.75 | 2024 | Xyosted |
| Sumitomo Pharma America, INC. | $31.79 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $26.76 | 2023 | Auvelity |
| Dynavax Technologies Corporation | $25.57 | 2024 | Heplisav-B |
| Shield Therapeutics INC | $23.07 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.35 | 2025 | Caplyta |
| Csl Behring | $16.14 | 2023 | Hizentra |
| Kowa Pharmaceuticals America, INC. | $15.57 | 2024 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $14.76 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrick Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.